M61.173
Myositis ossificans progressiva, unspecified ankle
Clinical Classification Guidelines
Medical Intelligence & Overview
Myositis ossificans progressiva (MOP), also known as fibrodysplasia ossificans progressiva, is a rare and serious genetic condition characterized by abnormal bone formation within muscles and other soft tissues. When it affects the ankle, it can lead to progressive stiffness, deformity, and restricted movement. This condition is distinct from other forms of myositis or soft tissue ossification because it is inherited and progresses over time, often worsening with age. Early diagnosis and understanding are vital for managing the condition, although there is no cure. The ICD-10 code M61.173 specifically points to cases involving the ankle, underscoring the localized nature of the disease in this region.
Causes & Symptoms
Clinical Causes: Genetic mutations: The primary cause of myositis ossificans progressiva is a genetic mutation affecting genes responsible for bone growth regulation, most notably the ACVR1 gene. Inheritance: The disorder is inherited in an autosomal dominant pattern, meaning a single copy of the altered gene from an affected parent can cause the condition. Triggering factors: While genetic predisposition is essential, trauma or injury to muscles may trigger or accelerate abnormal bone formation in some cases. Environmental factors: Although less established, certain environmental influences or exposures might contribute to disease progression in genetically susceptible individuals.
Key Symptoms: Progressive stiffness of the affected joints, especially in the ankles, neck, or shoulders. Gradual development of new bone growth within soft tissues following injury or spontaneously. Decreased range of motion over time, often leading to joint contractures. Deformities in the affected regions as abnormal bones fuse tissues and alter anatomy. Pain or discomfort in the areas of abnormal bone formation (though it may vary). Limited mobility that can interfere with daily activities and quality of life. In advanced stages, significant joint immobility and physical deformities.
Diagnostic & Treatment
Diagnosis Path: Medical history review: Including family history of similar conditions and previous injuries. Physical examination: Assessing joint mobility, visible deformities, and signs of soft tissue ossification. Imaging tests: X-rays are primary tools to visualize abnormal bone growth; MRI and CT scans may be used for detailed assessment. Genetic testing: Confirmatory testing for mutations in the ACVR1 gene or other related genetic markers. Biopsy: Rarely performed but can provide tissue samples to differentiate from other ossifying conditions.
Treatment Protocols: Symptom management: Focused on maintaining joint mobility and preventing deformities. Physical therapy: Tailored exercises to preserve as much range of motion as possible. Medications: Some drugs, such as corticosteroids, may help reduce inflammation during flare-ups. Surgical intervention: Generally avoided due to risk of exacerbating ossification, but may be considered for severe deformities or functional impairments. Emerging therapies: Research ongoing into gene-targeted treatments and medications to inhibit abnormal ossification processes.
Clinical Advice & FAQs
Billing Guidance
Is M61.173 a billable ICD-10 code?
Yes, M61.173 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M61.173?
Clinical documentation must specify the nature of Myositis ossificans progressiva, unspecified ankle and any associated comorbidities for accurate reporting.
Cite this Clinical Reference